Telomere Stack
79
상호작용
2
10,500
intermediate
May 17, 2026
개요
The Telomere Stack is a focused two-peptide protocol targeting chromosomal maintenance and cellular rejuvenation. Epithalon''s primary mechanism is activation of the catalytic subunit of telomerase (hTERT), the enzyme responsible for adding TTAGGG repeats to chromosome ends. In cell culture studies, Epithalon-treated fibroblasts showed a 33% increase in telomere length and extended their replicative lifespan by approximately 10 additional cell divisions beyond the Hayflick limit. In Khavinson''s longitudinal human studies, elderly patients receiving Epithalon showed normalized melatonin production, improved immune markers, and reduced all-cause mortality compared to controls over 6-12 year follow-up periods. GHK-Cu contributes to this stack through its remarkable gene expression modulation profile. Genome-wide studies reveal that GHK-Cu resets expression of numerous aging-related genes toward youthful patterns, including genes involved in DNA repair (GADD45A, XRCC1), antioxidant defense (SOD3, glutathione peroxidase), and anti-inflammatory pathways (IL-6 suppression, TGF-beta modulation). This transcriptomic "resetting" effect complements Epithalon''s telomere maintenance by ensuring that cells with preserved telomere length also maintain youthful functional capacity rather than persisting in a senescent-adjacent state. The stack follows a cyclical protocol: Epithalon is administered daily for 10 days, then discontinued for 4-6 months while GHK-Cu continues daily. This cycling is based on Khavinson''s research showing that telomerase activation occurs during the treatment window and persists for months afterward, making continuous administration unnecessary. GHK-Cu provides ongoing cellular maintenance between Epithalon cycles. This is one of the more conservative longevity stacks, suitable for individuals who want to address cellular aging biomarkers with well-characterized peptides.
용량 프로토콜
10,000 mcg
1회 용량당
500 mcg
1회 용량당
목표 및 증거
경고
- Epithalon was removed from the FDA Category 2 list (April 2026) but remains pending PCAC review (July 24, 2026) — not legal to compound yet. Telomere extension claims based on in-vitro and animal studies. Human longevity data is observational only.
Comments
Sign in to join the discussion
주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.